Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,918,120
  • Shares Outstanding, K 1,073,990
  • Annual Sales, $ 22,871 M
  • Annual Income, $ -204,100 K
  • 36-Month Beta 0.28
  • Price/Sales 4.97
  • Price/Cash Flow 19.09
  • Price/Book 9.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.35
  • Number of Estimates 5
  • High Estimate 1.42
  • Low Estimate 1.30
  • Prior Year 1.05
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.65 +2.58%
on 09/06/18
107.84 -1.40%
on 09/10/18
+1.26 (+1.20%)
since 08/21/18
3-Month
84.64 +25.63%
on 06/27/18
107.84 -1.40%
on 09/10/18
+20.26 (+23.54%)
since 06/21/18
52-Week
73.69 +44.29%
on 02/09/18
107.84 -1.40%
on 09/10/18
+23.00 (+27.60%)
since 09/21/17

Most Recent Stories

More News
Market Rallies Despite Trade Worries: 5 Blue-Chip Picks

The current momentum in stock markets can primarily attributed to large-cap blue-chip stocks as investors shrugged off trade war jitters.

WM : 91.42 (-0.33%)
CAT : 156.38 (+0.24%)
LLY : 106.33 (+0.25%)
RCI : 52.26 (+0.38%)
MET : 48.79 (+0.76%)
Lilly Receives Positive CHMP Opinion for Emgality(TM) (galcanezumab) for the Prophylaxis of Migraine in Adults

Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality(TM) (galcanezumab)...

LLY : 106.33 (+0.25%)
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

LLY : 106.33 (+0.25%)
ZTS : 89.83 (-0.26%)
NVS : 85.46 (-0.59%)
PFE : 44.06 (+0.71%)
GREATERGOOD.ORG JOINS FORCES WITH ELANCO ANIMAL HEALTH TO MEET CRITICAL HEALTH NEEDS TO HELP THOUSANDS OF PETS AFFECTED BY HURRICANE FLORENCE

GreaterGood.org is partnering with Elanco Animal Health, a subsidiary of Eli Lilly and Company (NYSE: LLY) to send two 53-foot long trailers (donated by Daum Trucking) carrying medical supplies to serve...

LLY : 106.33 (+0.25%)
Uptrend Call Working As Eli Lilly & Co Stock Rises 30.1% (LLY)

SmarTrend identified an Uptrend for Eli Lilly & Co (NYSE:LLY) on May 11th, 2018 at $81.74. In approximately 4 months, Eli Lilly & Co has returned 30.13% as of today's recent price of $106.36.

LLY : 106.33 (+0.25%)
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

JNJ : 142.88 (+0.63%)
MRK : 71.10 (+0.45%)
LLY : 106.33 (+0.25%)
PFE : 44.06 (+0.71%)
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

NVO : 47.66 (+0.34%)
LLY : 106.33 (+0.25%)
RHHBY : 30.6200 (+0.07%)
BMY : 62.25 (+0.81%)
Look for Shares of Eli Lilly & Co to Potentially Pullback after Yesterday's 1.03% Rise

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $105.11 to a high of $106.94. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

LLY : 106.33 (+0.25%)
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

BAYRY : 22.5000 (+0.04%)
LLY : 106.33 (+0.25%)
RHHBY : 30.6200 (+0.07%)
BMY : 62.25 (+0.81%)
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

JNJ : 142.88 (+0.63%)
LLY : 106.33 (+0.25%)
GSK : 40.30 (+1.08%)
PFE : 44.06 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 107.70
1st Resistance Point 107.02
Last Price 106.33
1st Support Level 105.50
2nd Support Level 104.66

See More

52-Week High 107.84
Last Price 106.33
Fibonacci 61.8% 94.79
Fibonacci 50% 90.76
Fibonacci 38.2% 86.74
52-Week Low 73.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar